MAP3K11/GDF15 axis is a critical driver of cancer cachexia.
Level 5 - mechanism / opinion, no new human data
Preclinical animal models and correlative human biomarker analysis
PubMed 27239403 · doi:10.1002/jcsm.12077
What was done
Researchers investigated molecular drivers of cancer cachexia using genetically engineered and xenograft mouse tumor models alongside plasma cytokine profiling from cachectic and non-cachectic cancer patients and mice. Gain-of-function and loss-of-function experiments were performed, including evaluating the therapeutic efficacy of a specific anti-GDF15 neutralizing antibody to reverse body weight, muscle, and fat loss in several cachectic mouse models.
What was found
The abstract reports no specific quantitative numbers or effect sizes. Qualitatively, activation of the MAP3K11/GDF15 pathway was identified as an inducer of cachexia, with tumor-derived GDF15 being sufficient to trigger cachectic symptoms in mice. High circulating GDF15 levels correlated with cachexia onset and progression in both mouse models and cancer patients. Antibody blockade of GDF15 reversed body weight loss and restored muscle and adipose mass across multiple animal models.
Why it matters
This study identifies GDF15 as a key functional mediator of cancer-associated wasting and demonstrates that targeted neutralization of GDF15 can reverse muscle and fat depletion in preclinical models, highlighting a potential therapeutic target.
Limits
The abstract provides no exact sample sizes for either human cohorts or animal groups, nor does it specify tumor types or quantitative outcome data. Therapeutic efficacy was demonstrated exclusively in preclinical mouse models, requiring clinical validation in human trials.
Cited by
- supports Cancer patients who develop cachexia exhibit elevated circulating levels of GDF15.